Ms. Linda F. Powers is the Chairman and Chief Executive Officer of Northwest Biotherapeutics (NW Bio), a publicly traded, NASDAQ listed Company developing personalized immune therapies for cancer. Ms. Powers has served as Chairman since May 2007, and as CEO June 2011.
Previously, Ms. Powers served as a Managing Director of Toucan Capital Fund II, a venture capital fund focused on immune therapy and regenerative medicine companies, commencing in 2001. She also has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions joint ventures and intellectual property licensing.
Ms. Powers is a Board member of M2GEN (an affiliate of Moffitt Cancer Center), the Chinese Biopharmaceutical Association, and the Rosalind Franklin Society. She serves on the MD Stem Cell Research Commission, and was the Commission Chair for the first two years of the state’s stem cell funding program. Ms. Powers served for more than 6 years on the Board of the Trudeau Institute (a specialized research institute focused on immunology). Ms. Powers served for several years on a Steering Committee of the National Academy of Sciences, evaluating government research funding, and has been appointed to three Governors’ commissions created to determine how to build the respective states’ biotech and other high-tech industries. Ms. Powers serves on the boards of a number of private biotechnology companies.
For six years, Ms. Powers taught an annual internal course at the U.S. National Institutes of Health, for bench scientists and technology transfer personnel, on the development and commercialization of house medical products. She also taught for eight years as an adjunct professor at Georgetown Law School.
Ms. Powers holds a B.A. from Princeton University, where she graduated magna cum laude and Phi Beta Kappa. She also earned a J.D., magna cum laude, from Harvard Law School.